Literature DB >> 26710712

Acalabrutinib for relapsed chronic lymphocytic leukaemia.

Talha Khan Burki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26710712     DOI: 10.1016/S1470-2045(15)00610-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

Authors:  Rick A Vreman; Joost W Geenen; Anke M Hövels; Wim G Goettsch; Hubert G M Leufkens; Maiwenn J Al
Journal:  Appl Health Econ Health Policy       Date:  2019-12       Impact factor: 2.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.